{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T02:39:30Z","timestamp":1778726370973,"version":"3.51.4"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2013,10,26]],"date-time":"2013-10-26T00:00:00Z","timestamp":1382745600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/2.5"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1007\/s40266-013-0126-4","type":"journal-article","created":{"date-parts":[[2013,10,25]],"date-time":"2013-10-25T17:16:05Z","timestamp":1382721365000},"page":"999-1008","source":"Crossref","is-referenced-by-count":14,"title":["Safety and Efficacy of Once-Daily Gastroretentive Gabapentin in Patients with Postherpetic Neuralgia Aged 75\u00a0Years and Over"],"prefix":"10.1007","volume":"30","author":[{"given":"Anita","family":"Gupta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,10,26]]},"reference":[{"issue":"7264","key":"126_CR1","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1136\/bmj.321.7264.778","volume":"321","author":"AL Cunningham","year":"2000","unstructured":"Cunningham AL, Dworkin RH. The management of post-herpetic neuralgia. BMJ. 2000;321(7264):778\u20139.","journal-title":"BMJ"},{"issue":"15","key":"126_CR2","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.2165\/00002018-200427150-00005","volume":"27","author":"MW Douglas","year":"2004","unstructured":"Douglas MW, Johnson RW, Cunningham AL. Tolerability of treatments for postherpetic neuralgia. Drug Saf. 2004;27(15):1217\u201333.","journal-title":"Drug Saf"},{"issue":"2","key":"126_CR3","doi-asserted-by":"crossref","first-page":"239","DOI":"10.36076\/ppj.2004\/7\/239","volume":"7","author":"D Niv","year":"2004","unstructured":"Niv D, Maltsman-Tseikhin A, Lang E. Postherpetic neuralgia: what do we know and where are we heading? Pain Physician. 2004;7(2):239\u201347.","journal-title":"Pain Physician"},{"issue":"8","key":"126_CR4","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/j.1525-1497.2005.0150.x","volume":"20","author":"RP Insinga","year":"2005","unstructured":"Insinga RP, Itzler RF, Pellissier JM, et al. The incidence of herpes zoster in a United States administrative database. J Gen Intern Med. 2005;20(8):748\u201353.","journal-title":"J Gen Intern Med"},{"key":"126_CR5","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/1471-2334-13-170","volume":"13","author":"S Pinchinat","year":"2013","unstructured":"Pinchinat S, Cebrian-Cuenca AM, Bricout H, et al. Similar herpes zoster incidence across Europe: results from a systematic literature review. BMC Infect Dis. 2013;13:170.","journal-title":"BMC Infect Dis"},{"issue":"11","key":"126_CR6","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.4065\/82.11.1341","volume":"82","author":"BP Yawn","year":"2007","unstructured":"Yawn BP, Saddier P, Wollan PC, et al. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc. 2007;82(11):1341\u20139.","journal-title":"Mayo Clin Proc"},{"issue":"11","key":"126_CR7","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1586\/14737175.7.11.1581","volume":"7","author":"RW Johnson","year":"2007","unstructured":"Johnson RW, Wasner G, Saddier P, et al. Postherpetic neuralgia: epidemiology, pathophysiology and management. Expert Rev Neurother. 2007;7(11):1581\u201395.","journal-title":"Expert Rev Neurother"},{"issue":"Suppl. 1","key":"126_CR8","first-page":"S1","volume":"42","author":"A Abdulla","year":"2013","unstructured":"Abdulla A, Adams N, Bone M, et al. Guidance on the management of pain in older people. Age Ageing. 2013;42(Suppl. 1):S1\u201357.","journal-title":"Age Ageing"},{"issue":"9696","key":"126_CR9","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/S0140-6736(09)61460-4","volume":"374","author":"K Christensen","year":"2009","unstructured":"Christensen K, Doblhammer G, Rau R, et al. Ageing populations: the challenges ahead. Lancet. 2009;374(9696):1196\u2013208.","journal-title":"Lancet"},{"key":"126_CR10","unstructured":"World Population Data Base [online]. http:\/\/www.census.gov\/population\/international\/data\/idb\/worldpop.php (Accessed 10 Sep 2013)."},{"key":"126_CR11","doi-asserted-by":"crossref","unstructured":"Persons AGSPoPPiO. The management of persistent pain in older persons. J Am Geriatr Soc. 2002;50 Suppl. 6:S205\u201324.","DOI":"10.1046\/j.1532-5415.50.6s.1.x"},{"issue":"3","key":"126_CR12","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1370\/afm.272","volume":"3","author":"M Fortin","year":"2005","unstructured":"Fortin M, Bravo G, Hudon C, et al. Prevalence of multimorbidity among adults seen in family practice. Ann Fam Med. 2005;3(3):223\u20138.","journal-title":"Ann Fam Med"},{"issue":"24","key":"126_CR13","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1001\/jama.2008.892","volume":"300","author":"DM Qato","year":"2008","unstructured":"Qato DM, Alexander GC, Conti RM, et al. Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA. 2008;300(24):2867\u201378.","journal-title":"JAMA"},{"issue":"1","key":"126_CR14","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/01.CNQ.0000306395.86905.8b","volume":"31","author":"NH Ballentine","year":"2008","unstructured":"Ballentine NH. Polypharmacy in the elderly: maximizing benefit, minimizing harm. Crit Care Nurs Q. 2008;31(1):40\u20135.","journal-title":"Crit Care Nurs Q"},{"issue":"16","key":"126_CR15","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1056\/NEJMsa020703","volume":"348","author":"TK Gandhi","year":"2003","unstructured":"Gandhi TK, Weingart SN, Borus J, et al. Adverse drug events in ambulatory care. N Engl J Med. 2003;348(16):1556\u201364.","journal-title":"N Engl J Med"},{"key":"126_CR16","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2147\/CIA.S30165","volume":"8","author":"R Rastogi","year":"2013","unstructured":"Rastogi R, Meek BD. Management of chronic pain in elderly, frail patients: finding a suitable, personalized method of control. Clin Interv Aging. 2013;8:37\u201346.","journal-title":"Clin Interv Aging"},{"issue":"5","key":"126_CR17","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3810\/pgm.2011.09.2469","volume":"123","author":"CE Argoff","year":"2011","unstructured":"Argoff CE. Review of current guidelines on the care of postherpetic neuralgia. Postgrad Med. 2011;123(5):134\u201342.","journal-title":"Postgrad Med"},{"issue":"2","key":"126_CR18","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1023\/A:1018951214146","volume":"10","author":"BH Stewart","year":"1993","unstructured":"Stewart BH, Kugler AR, Thompson PR, et al. A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma. Pharm Res. 1993;10(2):276\u201381.","journal-title":"Pharm Res"},{"key":"126_CR19","unstructured":"Pfizer. Neurontin\u00ae (gabapentin): prescribing information [online]. http:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=630 (Accessed 11 Apr 2013)."},{"issue":"1","key":"126_CR20","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s40261-012-0030-4","volume":"33","author":"P Johnson","year":"2013","unstructured":"Johnson P, Becker L, Halpern R, et al. Real-world treatment of post-herpetic neuralgia with gabapentin or pregabalin. Clin Drug Investig. 2013;33(1):35\u201344.","journal-title":"Clin Drug Investig"},{"issue":"9","key":"126_CR21","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1517\/17425247.2012.709231","volume":"9","author":"CE Argoff","year":"2012","unstructured":"Argoff CE, Chen C, Cowles VE. Clinical development of a once-daily gastroretentive formulation of gabapentin for treatment of postherpetic neuralgia: an overview. Expert Opin Drug Deliv. 2012;9(9):1147\u201360.","journal-title":"Expert Opin Drug Deliv"},{"issue":"4","key":"126_CR22","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1517\/17425247.3.4.541","volume":"3","author":"B Berner","year":"2006","unstructured":"Berner B, Cowles VE. Case studies in swelling polymeric gastric retentive tablets. Expert Opin Drug Deliv. 2006;3(4):541\u20138.","journal-title":"Expert Opin Drug Deliv"},{"issue":"4","key":"126_CR23","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1002\/jps.23467","volume":"102","author":"C Chen","year":"2013","unstructured":"Chen C, Han CH, Sweeney M, et al. Pharmacokinetics, efficacy, and tolerability of a once-daily gastroretentive dosage form of gabapentin for the treatment of postherpetic neuralgia. J Pharm Sci. 2013;102(4):1155\u201364.","journal-title":"J Pharm Sci"},{"issue":"11","key":"126_CR24","doi-asserted-by":"crossref","first-page":"765","DOI":"10.2165\/11539520-000000000-00000","volume":"30","author":"MS Wallace","year":"2010","unstructured":"Wallace MS, Irving G, Cowles VE. Gabapentin extended-release tablets for the treatment of patients with postherpetic neuralgia: a randomized, double-blind, placebo-controlled, multicentre study. Clin Drug Investig. 2010;30(11):765\u201376.","journal-title":"Clin Drug Investig"},{"issue":"4","key":"126_CR25","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/AJP.0b013e318258993e","volume":"29","author":"CN Sang","year":"2013","unstructured":"Sang CN, Sathyanarayana R, Sweeney M, et al. Gastroretentive gabapentin (G-GR) formulation reduces intensity of pain associated with postherpetic neuralgia (PHN). Clin J Pain. 2013;29(4):281\u20138.","journal-title":"Clin J Pain"},{"key":"126_CR26","first-page":"203","volume":"5","author":"GA Irving","year":"2012","unstructured":"Irving GA, Sweeney M. Tolerability and safety of gastroretentive once-daily gabapentin tablets for the treatment of postherpetic neuralgia. J Pain Res. 2012;5:203\u20138.","journal-title":"J Pain Res"},{"issue":"2","key":"126_CR27","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jpainsymman.2012.07.011","volume":"46","author":"RL Rauck","year":"2013","unstructured":"Rauck RL, Irving GA, Wallace MS, et al. Once-daily gastroretentive gabapentin for postherpetic neuralgia: integrated efficacy, time to onset of pain relief and safety analyses of data from two phase 3 multicenter, randomized, double-blind, placebo-controlled studies. J Pain Symptom Manage. 2013;46(2):219\u201328.","journal-title":"J Pain Symptom Manage"},{"issue":"5","key":"126_CR28","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/j.1365-2796.2011.02359.x","volume":"269","author":"D Gilden","year":"2011","unstructured":"Gilden D. Efficacy of live zoster vaccine in preventing zoster and postherpetic neuralgia. J Intern Med. 2011;269(5):496\u2013506.","journal-title":"J Intern Med"},{"key":"126_CR29","unstructured":"Merck. Zostavax\u00ae: prescribing information [online]. http:\/\/www.merck.com\/product\/usa\/pi_circulars\/z\/zostavax\/zostavax_pi2.pdf (Accessed 22 May 2013)."},{"issue":"11","key":"126_CR30","doi-asserted-by":"crossref","first-page":"e50553","DOI":"10.1371\/journal.pone.0050553","volume":"7","author":"K Annunziata","year":"2012","unstructured":"Annunziata K, Rak A, Del Buono H, et al. Vaccination rates among the general adult population and high-risk groups in the United States. PLoS One. 2012;7(11):e50553.","journal-title":"PLoS One"},{"key":"126_CR31","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1741-7015-8-37","volume":"8","author":"RW Johnson","year":"2010","unstructured":"Johnson RW, Bouhassira D, Kassianos G, et al. The impact of herpes zoster and post-herpetic neuralgia on quality-of-life. BMC Med. 2010;8:37.","journal-title":"BMC Med"},{"issue":"3 Suppl. 3","key":"126_CR32","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.4065\/mcp.2009.0646","volume":"85","author":"KE Schmader","year":"2010","unstructured":"Schmader KE, Baron R, Haanpaa ML, et al. Treatment considerations for elderly and frail patients with neuropathic pain. Mayo Clin Proc. 2010;85(3 Suppl. 3):S26\u201332.","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"126_CR33","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/j.1532-5415.2012.03923.x","volume":"60","author":"American Geriatrics Society Beers Criteria Update Expert Panel","year":"2012","unstructured":"American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2012;60(4):616\u201331.","journal-title":"J Am Geriatr Soc"},{"issue":"8","key":"126_CR34","doi-asserted-by":"crossref","first-page":"348","DOI":"10.4297\/najms.2011.3348","volume":"3","author":"RR Dalacorte","year":"2011","unstructured":"Dalacorte RR, Rigo JC, Dalacorte A. Pain management in the elderly at the end of life. N Am J Med Sci. 2011;3(8):348\u201354.","journal-title":"N Am J Med Sci"},{"issue":"7","key":"126_CR35","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1086\/368196","volume":"36","author":"RH Dworkin","year":"2003","unstructured":"Dworkin RH, Schmader KE. Treatment and prevention of postherpetic neuralgia. Clin Infect Dis. 2003;36(7):877\u201382.","journal-title":"Clin Infect Dis"},{"issue":"Suppl. 11","key":"126_CR36","first-page":"S288","volume":"17","author":"JV Pergolizzi","year":"2011","unstructured":"Pergolizzi JV. Quantifying the impact of drug\u2013drug interactions associated with opioids. Am J Manage Care. 2011;17(Suppl. 11):S288\u201392.","journal-title":"Am J Manage Care"},{"issue":"1","key":"126_CR37","first-page":"67","volume":"8","author":"C Chen","year":"2013","unstructured":"Chen C, Cowles VE, Sweeney M. The intestinal absorption mechanism of gabapentin makes it appropriate for gastroretentive delivery. Curr Clin Pharmacol. 2013;8(1):67\u201372.","journal-title":"Curr Clin Pharmacol"},{"issue":"2","key":"126_CR38","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0304-3959(01)00349-9","volume":"94","author":"JD Farrar","year":"2001","unstructured":"Farrar JD, Young JPJ, LaMoreaux L, et al. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 2001;94(2):149\u201358.","journal-title":"Pain"},{"issue":"2","key":"126_CR39","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jpain.2007.09.005","volume":"9","author":"RH Dworkin","year":"2008","unstructured":"Dworkin RH, Turk DC, Wyrwich KW, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain. 2008;9(2):105\u201321.","journal-title":"J Pain"},{"issue":"5","key":"126_CR40","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.clinthera.2013.03.008","volume":"35","author":"A Vinik","year":"2013","unstructured":"Vinik A, Emir B, Cheung R, et al. Relationship between pain relief and improvements in patient function\/quality of life in patients with painful diabetic peripheral neuropathy or postherpetic neuralgia treated with pregabalin. Clin Ther. 2013;35(5):612\u201323.","journal-title":"Clin Ther"},{"issue":"2","key":"126_CR41","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0304-3959(01)00407-9","volume":"94","author":"AS Rice","year":"2001","unstructured":"Rice AS, Maton S, Postherpetic Neuralgia Study Group. Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study. Pain. 2001;94(2):215\u201324.","journal-title":"Pain"},{"issue":"21","key":"126_CR42","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1001\/jama.280.21.1837","volume":"280","author":"M Rowbotham","year":"1998","unstructured":"Rowbotham M, Harden N, Stacey B, et al. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA. 1998;280(21):1837\u201342.","journal-title":"JAMA"}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40266-013-0126-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-013-0126-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-013-0126-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,10]],"date-time":"2022-03-10T16:28:22Z","timestamp":1646929702000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40266-013-0126-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,26]]},"references-count":42,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["126"],"URL":"https:\/\/doi.org\/10.1007\/s40266-013-0126-4","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,26]]}}}